Abstract 17P
Background
Ovarian cancer is the most lethal gynecological malignancy worldwide and is known to have a poor prognosis among gynecological cancers. Recently, PD-1/PD-L1 inhibitors have demonstrated promising clinical outcomes in the treatment of OC. However, only about 20% of patients respond to these therapies, highlighting the need for improved patient selection. LncRNAs are significantly involved in tumor proliferation, apoptosis, migration, and metastasis and have significant associations with immune cell infiltration and the cancer cell response to anti-PD-1 immunotherapy in various tumors. Based on reports that immune-related lncRNAs play a role in regulating the PD-1/PD-L1 mechanism, this study aims to identify predictive biomarkers for ovarian cancer.
Methods
We analyzed the mRNA and protein levels of PD-L1 in OC patient tissues and classified them into high and low PD-L1 expression groups. We performed lncRNA microarray analysis on the classified groups. As a result, we identified MIR4435-2HG as lncRNA associated with PD-L1 overexpression. Furthermore, MIR4435-2HG knockdown were conducted. Other features, including cell growth, apoptosis, migration and invasion were also analyzed.
Results
A positive correlation between PD-L1 and MIR4435-2HG was observed in both OC tissues and cell lines. Knockdown of MIR4435-2HG in OC cell lines resulted in decreased PD-L1 expression and induce cellular apoptosis and inhibit cell migration and invasion. Moreover, GO analysis revealed that MIR4435-2HG is associated to immune-related genes.
Conclusions
Therefore, this study suggests that the lncRNA MIR4435-2HG associated with PD-L1 may be used as a predictive biomarker and therapeutic target in ovarian cancer.
Legal entity responsible for the study
The Catholic University of Korea, Industry-Academic Cooperation Foundation.
Funding
The National Research Foundation of Korea (NRF).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract